Scarica l'app Stockscreener
96.75
0.03%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVTY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$96.78
Aprire:
$96.97
Volume 24 ore:
557.14K
Relative Volume:
0.40
Capitalizzazione di mercato:
$10.97B
Reddito:
$2.77B
Utile/perdita netta:
$286.61M
Rapporto P/E:
41.17
EPS:
2.35
Flusso di cassa netto:
$524.11M
1 W Prestazione:
+0.53%
1M Prestazione:
-7.56%
6M Prestazione:
-2.06%
1 anno Prestazione:
-14.00%
Intervallo 1D:
$95.87
$97.09
Intervallo di 1 settimana:
$95.87
$98.55
Portata 52W:
$81.36
$128.28
Revvity Inc Stock (RVTY) Company Profile
Nome
Revvity Inc
Settore
Industria
Telefono
781-663-6900
Indirizzo
77 4TH AVENUE, WALTHAM
Confronta RVTY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
96.75 | 10.97B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
580.74 | 217.58B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
230.32 | 163.50B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
688.48 | 54.95B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
138.39 | 39.21B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
226.92 | 38.49B | 15.90B | 1.28B | 2.21B | 7.2842 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-12-09 | Iniziato | Goldman | Neutral |
| 2025-10-16 | Iniziato | Guggenheim | Neutral |
| 2025-05-01 | Aggiornamento | UBS | Neutral → Buy |
| 2025-01-10 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-15 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-07-08 | Iniziato | Leerink Partners | Outperform |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-01-04 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Iniziato | Wells Fargo | Equal Weight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-05-23 | Ripresa | Goldman | Buy |
Mostra tutto
Revvity Inc Borsa (RVTY) Ultime notizie
Can Revvity Inc. stock deliver strong annual returnsPortfolio Risk Assessment & Rapid Portfolio Trading - bollywoodhelpline.com
Revvity Earnings Notes - Trefis
Revvity advances AI-driven scientific discovery with Signals Xynthetica - MSN
Q3 Earnings Highlights: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
(RVTY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat? - simplywall.st
Revvity introduces AI-augmented design platform for molecular and materials discovery - BioSpectrum India
Aug Patterns: How Revvity Inc stock reacts to global recession fearsJuly 2025 Summary & Safe Capital Growth Trade Ideas - moha.gov.vn
Is Revvity Inc. stock a defensive play in 2025Global Markets & Stepwise Trade Signal Implementation - Улправда
How cyclical is Revvity Inc. stock compared to rivalsJuly 2025 Price Swings & Comprehensive Market Scan Reports - DonanımHaber
Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica - TradingView — Track All Markets
Will Revvity Inc. stock reach all time highs in 2025Weekly Trade Report & Expert Verified Stock Movement Alerts - DonanımHaber
Raymond James reiterates Outperform rating on Revvity stock after site visit - Investing.com Nigeria
Raymond James reiterates Outperform rating on Revvity stock after site visit By Investing.com - Investing.com India
What consensus target says about Revvity Inc. stockRate Cut & AI Optimized Trade Strategies - DonanımHaber
Why Revvity Inc. stock could outperform in 2025Weekly Profit Analysis & Precise Buy Zone Tips - DonanımHaber
Will Revvity Inc. stock benefit from automationJuly 2025 Closing Moves & Technical Buy Zone Confirmations - Улправда
Is Revvity Inc. stock a buy on dipsWeekly Trading Summary & Daily Price Action Insights - Улправда
What analyst consensus says on Revvity Inc. stockInsider Selling & Proven Capital Preservation Tips - Улправда
Revvity (BSP:R1VT34) EV-to-OCF : 22.14 (As of Dec. 18, 2025) - GuruFocus
Will Revvity Inc. stock see PE expansionMarket Activity Summary & High Conviction Buy Zone Picks - ulpravda.ru
Revvity to Present at J.P. Morgan Healthcare Conference - Business Wire
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet? - simplywall.st
How is Revvity's stock performance compared to other health care stocks? - MSN
Revvity (NYSE: RVTY) officer disposes 25 shares for RSU tax withholding - Stock Titan
3 Reasons RVTY is Risky and 1 Stock to Buy Instead - The Globe and Mail
Revvity unveils AI-powered Signals Xynthetica to accelerate molecular and materials design - Indian Pharma Post
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Revvity to launch AI models-as-a-service for scientific discovery - Investing.com Nigeria
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials D - PharmiWeb.com
Revvity Introduces New AI Service for Molecular, Materials Design - marketscreener.com
Revvity, Inc. Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery - marketscreener.com
Barclays Maintains Revvity (RVTY) Overweight Recommendation - Nasdaq
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery - Yahoo Finance
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Shares Fall After BofA Downgrade - marketscreener.com
Revvity stock rating downgraded to Neutral by BofA Securities - Investing.com South Africa
Revvity (NYSE:RVTY) Lowered to "Neutral" Rating by Bank of America - MarketBeat
Barclays Adjusts Price Target on Revvity to $115 From $105, Maintains Overweight Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Revvity to $107 From $102, Maintains Equalweight Rating - marketscreener.com
BofA Securities Downgrades Revvity to Neutral From Buy - marketscreener.com
How Is Revvity's Stock Performance Compared to Other Health Care Stocks? - Barchart.com
EdgePoint Investment Group Inc. Boosts Stock Position in Revvity Inc. $RVTY - MarketBeat
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Federated Hermes Inc. Cuts Position in Revvity Inc. $RVTY - MarketBeat
The Goldman Sachs Group Begins Coverage on Revvity (NYSE:RVTY) - MarketBeat
Goldman Sachs initiates coverage of Revvity (RVTY) with neutral recommendation - MSN
Revvity Inc Azioni (RVTY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):